Page 89 - Drug Class Review
P. 89
Drug Effectiveness Review Project
Alzheimer classification: Mild to moderate
Groups similar at baseline: Yes
galantamine PRC placebo galantamine 76.3 76.5 76.6 64 64 64 4% 4% 3% 90% 90% 93% 2% 2% 1% 2% 2% 3% 2% 3% 1% 18.08 17.8 17.96 Primary Outcome Measures: ADAS-cog/11 score; CIBIC-plus score Secondary Outcome Measures: ADCS-ADL; NPI Timing of assessments: Screening, baseline, and weeks 4,8,12, and 26 Health Outcome Measures: Both galantamine treatments were significantly more effective than placebo as measured by the ADAS-cog/11 score (P < 0.001 galantamine PRC, P < 0.01 for galantamine) No statistically significa
• • • • •
Final Report Update 1 Authors: Brodaty et al. Year: 2005 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Black: White: Hispanic: Asian: Other: Other germane population qualities: MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
